



## Evaluation Report for Category B, Subcategory B.3.10 Application (New or Changes to Product Label – Tank Mixes)

**Application Number:** 2024-1642  
**Application:** Category B.3.10 (New or changes to product label – Tank mixes)  
**Product:** Varro FX  
**Registration Number:** 34848  
**Active Ingredients (a.i.):** 5 g/L thiencazuron-methyl and 118 g/L fluroxypyr present as 1-methylheptyl ester)  
**PMRA Document Number:** 3607321

### Purpose of Application

The purpose of this application is to amend the registration of Varro FX to include the amendments that are listed below:

1. Add the general tank mix statement as per the published PMRA Guidance Document – Tank Mix Labelling.
2. Include additional tank mixing statements to accompany the general tank mixing statement above.
3. Include a restrictive statement for using in combination with other Group 27 Herbicides: *DO NOT tank-mix Varro FX with herbicides, containing the following active ingredients: bicyclopyrone (e.g., Talinor Herbicide) and tolypyralate (e.g., OnDeck Herbicide).*

Other minor label amendments are also requested.

### Chemistry, Health, and Environmental Assessments

Chemistry, health, and environmental assessments were not required as there was no change to product chemistry, product formulation, or use pattern.

### Value Assessment

A thorough review of the label determined that the addition of the general tank mix statement is acceptable as it is consistent with the requirements in the PMRA Guidance Document – Tank Mix Labelling.

The inclusion of the general tank mixing statement on the label allows growers greater flexibility to select tank mixtures to control pests in labelled crops. Flexibility in the selection of tank mix partners may contribute to resistance management practices, integrated weed management programs, or the control of a broader range of pests, with an associated cost- and time-savings by the user.

Other label amendments, including the addition of additional tank mixing statements and the restrictive statement, are supported based on rationales and relevant precedent registrations.

**Conclusion**

The PMRA has completed an assessment of the subject application and has found the information sufficient to support all the requested amendments to the Varro FX label.

## **References**

List of Studies/Information Submitted by Registrant

None

**© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2024**

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.